News Daily News Secondary Prevention Lagging Behind in Women With Established Coronary Disease Todd Neale September 22, 2017
News Conference News ESC 2017 Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1 Michael O'Riordan September 05, 2017
News Conference News ESC 2017 Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets Michael O'Riordan August 30, 2017
News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
Presentation ESC 2017 Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial Presenter: Robert Giugliano August 28, 2017
News Conference News ESC 2017 Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab Michael O'Riordan August 28, 2017
News Daily News Evolocumab Not Cost-Effective at Current List Price Michael O'Riordan August 23, 2017
News Daily News Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness Michael O'Riordan August 08, 2017
News Daily News ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year Yael L. Maxwell August 07, 2017
News Daily News ‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low Michael O'Riordan August 01, 2017
News Daily News Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke Michael O'Riordan July 25, 2017
News Daily News Black Men Have Twofold Higher Risk of Dying From First CHD Event Michael O'Riordan July 10, 2017
News Daily News Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound Todd Neale June 27, 2017
News Daily News Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease L.A. McKeown June 12, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for May 2017 Shelley Wood June 01, 2017
News Features How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts Michael O'Riordan May 23, 2017
News Daily News $2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor Michael O'Riordan May 12, 2017
News Daily News ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events Michael O'Riordan April 04, 2017